NCT01495585View on ClinicalTrials.gov

Lonafarnib for Chronic Hepatitis D

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions
Hepatitis D
Interventions
DRUG

Lonafarnib

Commercially approved products used to test the research hypothesis

OTHER

Placebo

Placebo control

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

NCT01495585 - Lonafarnib for Chronic Hepatitis D | Biotech Hunter | Biotech Hunter